Illustrative only
Market attractiveness
Market attractiveness for Heart Failure: strong on epidemiology and residual unmet need, weak on pricing potential.
- Epidemiology attractivenessLarge, well-characterised HFrEF population4.5 / 5
- Residual unmet needEvents persist on optimised therapy4 / 5
- Competitive intensity14 Phase III programmes on top of four foundational classes2 / 5
- Pricing potentialThree of seven classes anchor below $200 a year2.5 / 5
- Clinical differentiation requiredA gain has to be shown on top of quadruple therapy2 / 5
- Development / regulatory riskEvent-driven outcome trials, precedented endpoints3 / 5
Verdict
Attractive on epidemiology and residual unmet need; constrained by the price a chronic oral entrant can command and by the differentiation it has to show on top of four foundational classes.
What would change the call
An add-on that cuts HF hospitalisations by at least 12% on top of quadruple therapy, priced inside the $4,600–$6,400 corridor.
0–5 = attractiveness. A crowded market or a high bar scores low.
So what?
Only 22% of treated HFrEF patients are on all four foundational classes – the headroom for an add-on sits inside the treated pool.
Residual event risk on optimised therapy is the largest unmet need – and the only dimension priced at the top of the corridor.
Three of seven marketed classes anchor below $200 a year, which caps the price a chronic oral entrant can command.
Changed since last refresh
SGLT2 inhibitor share of treated moved 34% → 39%; the addressable estimate moved 410,000 → 430,000.